The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALGS | -25.43% | -98.06% | -54.53% | -98% |
| S&P | +17.53% | +93.66% | +14.13% | +95% |
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.97M | -9.0% |
| Gross Profit | $0.71M | 56.5% |
| Gross Margin | 73.16% | 30.7% |
| Market Cap | $44.09M | 66.5% |
| Market Cap / Employee | $0.63M | 0.0% |
| Employees | 70 | 6.1% |
| Net Income | -$15.86M | -413.4% |
| EBITDA | -$18.31M | 29.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $18.77M | -58.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.34M | -48.5% |
| Short Term Debt | $3.54M | 5.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -60.93% | 9.5% |
| Return On Invested Capital | 52.11% | 117.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$15.61M | 19.9% |
| Operating Free Cash Flow | -$15.50M | 20.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.41 | 2.64 | -1.10 | 0.38 | -14.52% |
| Price to Sales | 9.06 | 63.44 | 21.97 | 23.51 | 241.68% |
| Price to Tangible Book Value | 0.41 | 2.64 | -1.10 | 0.38 | -14.52% |
| Enterprise Value to EBITDA | 0.59 | -10.13 | 3.06 | 2.27 | 95.56% |
| Return on Equity | -146.7% | -415.8% | -60.4% | -87.7% | -20.72% |
| Total Debt | $9.13M | $8.38M | $7.87M | $6.88M | -30.08% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
